[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100514245":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":28,"locations":36,"responsibleParty":155,"collaborators":25,"id":157,"slug":158,"hasResults":159,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":25,"eligibilityCriteria":163,"healthyVolunteers":159,"sex":164,"minAge":165,"maxAge":25,"enrollmentInfo":166,"targetDuration":25,"studyType":169,"phases":170,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":192},{"fullName":5,"class":6},"InSilico Medicine Hong Kong Limited","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"INS018_055","EXPERIMENTAL","INS018\\_055 is administered once daily up to 12 weeks",[13],"Drug: INS018_055",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo is administered once daily up to 12 weeks",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Pharmaceutical formulation: Tablet\n\nMode of Administration: Oral",[9],null,{"type":22,"name":15,"description":23,"armGroupLabels":27,"otherNames":25},[15],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":25,"email":33},"Monique Duncan","CONTACT","+86 18817554306","Insilico-Clinicaltrial@insilico.ai",{"name":35,"role":31,"phone":25,"phoneExt":25,"email":33},"Carol Salter, MD, PhD",[37,51,61,71,81,90,100,110,120,130,140,149],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":25},"University of Alabama at Birmingham","RECRUITING","Birmingham","Alabama","35294","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-86.80249,33.52066,{"lat":49,"lon":48},{"facility":52,"status":39,"city":53,"state":54,"zip":55,"country":43,"countryCode":44,"cosmosGeoPoint":56,"geoPoint":60,"contacts":25},"HonorHealth Research Institute","Scottsdale","Arizona","85258",{"type":46,"coordinates":57},[58,59],-111.89903,33.50921,{"lat":59,"lon":58},{"facility":62,"status":39,"city":63,"state":64,"zip":65,"country":43,"countryCode":44,"cosmosGeoPoint":66,"geoPoint":70,"contacts":25},"Keck School of Medicine of USC","Los Angeles","California","90033",{"type":46,"coordinates":67},[68,69],-118.24368,34.05223,{"lat":69,"lon":68},{"facility":72,"status":39,"city":73,"state":74,"zip":75,"country":43,"countryCode":44,"cosmosGeoPoint":76,"geoPoint":80,"contacts":25},"Florida Lung Asthma and Sleep Specialist","Celebration","Florida","34747-1818",{"type":46,"coordinates":77},[78,79],-81.53313,28.32529,{"lat":79,"lon":78},{"facility":82,"status":39,"city":83,"state":74,"zip":84,"country":43,"countryCode":44,"cosmosGeoPoint":85,"geoPoint":89,"contacts":25},"Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando","Orlando","32803-5727",{"type":46,"coordinates":86},[87,88],-81.37924,28.53834,{"lat":88,"lon":87},{"facility":91,"status":39,"city":92,"state":93,"zip":94,"country":43,"countryCode":44,"cosmosGeoPoint":95,"geoPoint":99,"contacts":25},"Southeastern Research Center","Winston-Salem","North Carolina","27103-4007",{"type":46,"coordinates":96},[97,98],-80.24422,36.09986,{"lat":98,"lon":97},{"facility":101,"status":39,"city":102,"state":103,"zip":104,"country":43,"countryCode":44,"cosmosGeoPoint":105,"geoPoint":109,"contacts":25},"University of Oklahoma Health Sciences Center (OUHSC)","Oklahoma City","Oklahoma","73104-5417",{"type":46,"coordinates":106},[107,108],-97.51643,35.46756,{"lat":108,"lon":107},{"facility":111,"status":39,"city":112,"state":113,"zip":114,"country":43,"countryCode":44,"cosmosGeoPoint":115,"geoPoint":119,"contacts":25},"Temple University Hospital-Temple Lung Center","Philadelphia","Pennsylvania","19140",{"type":46,"coordinates":116},[117,118],-75.16362,39.95238,{"lat":118,"lon":117},{"facility":121,"status":39,"city":122,"state":123,"zip":124,"country":43,"countryCode":44,"cosmosGeoPoint":125,"geoPoint":129,"contacts":25},"Bogan Sleep Consultants, LLC","Columbia","South Carolina","29201-2953",{"type":46,"coordinates":126},[127,128],-81.03481,34.00071,{"lat":128,"lon":127},{"facility":131,"status":39,"city":132,"state":133,"zip":134,"country":43,"countryCode":44,"cosmosGeoPoint":135,"geoPoint":139,"contacts":25},"University of Texas Southwestern Medical Center","Dallas","Texas","75235-6243",{"type":46,"coordinates":136},[137,138],-96.80667,32.78306,{"lat":138,"lon":137},{"facility":141,"status":39,"city":142,"state":133,"zip":143,"country":43,"countryCode":44,"cosmosGeoPoint":144,"geoPoint":148,"contacts":25},"Metroplex Pulmonary and Sleep Center","McKinney","75069-1898",{"type":46,"coordinates":145},[146,147],-96.61527,33.19762,{"lat":147,"lon":146},{"facility":150,"status":39,"city":142,"state":133,"zip":151,"country":43,"countryCode":44,"cosmosGeoPoint":152,"geoPoint":154,"contacts":25},"Research Centers of America","75071",{"type":46,"coordinates":153},[146,147],{"lat":147,"lon":146},{"type":156,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100514245","phase-2-study-evaluating-ins018055-administered-orally-to-subjects-with-idiopathic-pulmonary-fibrosis-100514245",false,"NCT05975983","Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis","A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)","Inclusion Criteria:\n\n1. Male or female patients aged ≥40 years based on the date of the written informed consent form\n2. Diagnosis of IPF as defined by American Thoracic Society\u002FEuropean Respiratory Society\u002FJapanese Respiratory Society\u002FLatin American Thoracic Association guidelines\n3. In a stable condition and suitable for study participation based on the results of medical history, physical examination, vital signs, 12-lead ECG, and laboratory evaluation\n4. Meeting all of the following criteria during the screening period:\n\n   1. FVC ≥40% predicted normal\n   2. DLCO corrected for Hgb ≥25% and \\\u003C80% predicted normal\n   3. Forced Expiratory Volume in the first second\u002FFVC (FEV1\u002FFVC) ratio \\>0.7 based on pre-bronchodilator value\n\nExclusion Criteria:\n\n1. Acute IPF exacerbation within 4 months prior to Visit 1 and\u002For Day 1, as determined by the investigator\n2. Patients who are unwilling to refrain from smoking within 3 months prior to screening and until the end of the study\n3. Female patients who are pregnant or nursing\n4. Abnormal ECG findings","ALL","40 Years",{"count":167,"type":168},40,"ESTIMATED","INTERVENTIONAL",[171],"PHASE2","The purpose of this revised Phase IIa study is to demonstrate safety of INS018\\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).",[174],"Idiopathic Pulmonary Fibrosis (IPF)",[176,177,178,179,180,181,182],"Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis","Fibrosis","Pathologic Processes","Lung Diseases, Interstitial","Lung Diseases","Respiratory Tract Diseases","2025-11-10",{"date":185,"type":186},"2025-11-12","ACTUAL",{"date":188,"type":186},"2024-02-08",{"date":190,"type":168},"2026-02-28",{"name":5,"class":6},12]